# Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

> **NCT03642067** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 59 (actual)

## Conditions studied

- Microsatellite Stable (MSS) Colorectal Adenocarcinomas
- Colorectal Adenocarcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Relatlimab

## Key facts

- **NCT ID:** NCT03642067
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-12
- **Primary completion:** 2024-02-23
- **Final completion:** 2024-09-18
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03642067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03642067, "Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03642067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*